Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma

Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma

Background and Aims: The prognosis of patients with advanced hepatocellular carcinoma (HCC) is expected to improve as multiple molecular target agents (MTAs) are now available. However, the impact of the availability of sequential MTAs has not been fully verified yet. Approach and Results: We retros...

Full description

Bibliographic Details
Main Authors: Kazufumi Kobayashi, Sadahisa Ogasawara, Aya Takahashi, Yuya Seko, Hidemi Unozawa, Rui Sato, Shunji Watanabe, Michihisa Moriguchi, Naoki Morimoto, Satoshi Tsuchiya, Kenji Iwai, Masanori Inoue, Keita Ogawa, Takamasa Ishino, Terunao Iwanaga, Takafumi Sakuma, Naoto Fujita, Hiroaki Kanzaki, Keisuke Koroki, Masato Nakamura, Naoya Kanogawa, Soichiro Kiyono, Takayuki Kondo, Tomoko Saito, Ryo Nakagawa, Eiichiro Suzuki, Yoshihiko Ooka, Shingo Nakamoto, Akinobu Tawada, Tetsuhiro Chiba, Makoto Arai, Tatsuo Kanda, Hitoshi Maruyama, Kengo Nagashima, Jun Kato, Norio Isoda, Takeshi Aramaki, Yoshito Itoh, Naoya Kato
Format: Article
Language:English
Published: Karger Publishers 2021-12-01
Series:Liver Cancer
Subjects:
sequential therapy
sorafenib
regorafenib
lenvatinib
ramucirumab
Online Access:https://www.karger.com/Article/FullText/519868

Similar Items

Similar Items